All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $0.07 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2020
Details:
Funds will be used for screening project between Daiichi Sankyo RD Novare and DNDi for hit identification of a Chagas disease, Leishmaniasis Drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab Deruxtecan
Therapeutic Area: Oncology Product Name: Enhertu
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
ENHERTU is the first and only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for patients with previously treated HER2 positive advanced gastric cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Patritumab Deruxtecan
Therapeutic Area: Oncology Product Name: U3-1402
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Patritumab Deruxtecan
Therapeutic Area: Oncology Product Name: U3-1402
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
The Phase 2 study will evaluate patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, in previously treated patients with HER3 expressing advanced/metastatic colorectal cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Edoxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Du-176b
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
This application is based on results from the Japanese phase 3 clinical trial (ELDERCARE-AF Study) in 984 non-valvular atrial fibrillation patients of 80 years and above with a high bleeding risk and who are ineligible for other available anticoagulation therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-5670
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
The vaccine, known as DS-5670, was picked for the second round of AMED’s program dedicated to COVID-19 research. Daiichi Sankyo is aiming to begin clinical studies of the vaccine around March 2021 in collaboration with the University of Tokyo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Edoxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Du-176b
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Primary endpoint has been achieved in the Japan phase 3 clinical trial (ELDERCARE AF Study; hereinafter, the study) for the anticoagulant, edoxaban, in elderly patients with non-valvular atrial fibrillation and high bleeding risk.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bempedoic Acid
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nilemdo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Daiichi Sankyo Europe GmbH announced that NILEMDO® (bempedoic acid) has demonstrated consistent tolerability and sustained efficacy over 2.5 years, in results presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-5670
Highest Development Status: Undisclosed Product Type: Vaccine
Partner/Sponsor/Collaborator: Ministry of Health, Labour and Welfare of Japan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 08, 2020
Details:
DS-5670 is a gene (mRNA) vaccine for COVID-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo, and as one of the company’s top-priority projects, it is being prepared to enter clinical studies around March 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Patritumab Deruxtecan,Osimertinib
Therapeutic Area: Oncology Product Name: U3-1402
Highest Development Status: Phase I Product Type: Large molecule
Recipient: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 06, 2020
Details:
The collaboration aims to evaluate the combination of patritumab deruxtecan (U3-1402) and TAGRISSO (osimertinib) in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
